Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 1,420,000 shares, an increase of 19.3% from the March 15th total of 1,190,000 shares. Approximately 3.2% of the company's shares are short sold. Based on an average daily trading volume, of 250,000 shares, the short-interest ratio is currently 5.7 days.
Wall Street Analysts Forecast Growth
AURA has been the topic of several analyst reports. HC Wainwright set a $25.00 price objective on Aura Biosciences in a report on Tuesday, March 25th. Citigroup restated an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. JMP Securities set a $19.00 price objective on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Aura Biosciences presently has an average rating of "Buy" and a consensus price target of $22.75.
Read Our Latest Stock Report on AURA
Aura Biosciences Stock Performance
Shares of NASDAQ:AURA traded down $0.14 during trading on Friday, reaching $5.38. 244,554 shares of the stock were exchanged, compared to its average volume of 201,598. The firm's 50-day moving average price is $6.52 and its 200 day moving average price is $8.08. The firm has a market cap of $270.21 million, a price-to-earnings ratio of -3.11 and a beta of 0.43. Aura Biosciences has a 12-month low of $4.84 and a 12-month high of $12.38.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09). As a group, equities research analysts forecast that Aura Biosciences will post -1.66 EPS for the current year.
Insider Activity
In other Aura Biosciences news, insider Conor Kilroy sold 7,162 shares of Aura Biosciences stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total value of $39,319.38. Following the completion of the sale, the insider now directly owns 179,313 shares of the company's stock, valued at approximately $984,428.37. The trade was a 3.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 14,148 shares of company stock valued at $91,434 over the last 90 days. Insiders own 5.40% of the company's stock.
Institutional Trading of Aura Biosciences
Large investors have recently added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. purchased a new stake in shares of Aura Biosciences in the first quarter worth about $151,000. GAMMA Investing LLC lifted its position in Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock worth $57,000 after acquiring an additional 9,573 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Aura Biosciences by 12.6% in the 4th quarter. Wellington Management Group LLP now owns 131,054 shares of the company's stock worth $1,077,000 after acquiring an additional 14,662 shares during the period. ProShare Advisors LLC acquired a new stake in Aura Biosciences in the fourth quarter valued at approximately $127,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Aura Biosciences by 27.7% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,516 shares of the company's stock valued at $1,122,000 after purchasing an additional 29,618 shares during the period. 96.75% of the stock is currently owned by institutional investors and hedge funds.
Aura Biosciences Company Profile
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Further Reading
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
